Yoon‐Koo Kang

5 ta ish

University of Ulsan

1. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

   David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad +20

   MaqolaOAOchiq kirish20206 iqtibos

   ABIABI:AkademIndex/2026.other.213689

2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

   Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova +13

   MaqolaOAOchiq kirish20105 iqtibos

   ABIABI:AkademIndex/2026.other.192778

3. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

   Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen +18

   Maqola20082 iqtibos

   ABIABI:AkademIndex/2026.other.548033

4. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines

   Toshirou Nishida, Jean‐Yves Blay, Seiichi Hirota +2

   Sharh maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.596876

5. Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck

   Cheolwon Suh, Yoon‐Koo Kang, Jong‐Lyel Roh +6

   MaqolaOAOchiq kirish20080 iqtibos

   ABIABI:AkademIndex/2008.article.000550